OncLive SOSS

Authors

Natalia Neparidze, MD

Latest:

Bispecific Antibodies for the Treatment of RRMM in the Post CAR T Setting

Panelists discuss how the transition from chimeric antigen receptor T-cell therapy (CAR T) to bispecific antibodies depends on disease progression and clinical status, with the choice of bispecific antibody being guided by prior therapy and target antigen, preferring B-cell maturation antigen (BCMA) bispecifics for BCMA-exposed patients and GPRC5D bispecifics for those with BCMA-relapsed disease.

M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP

Latest:

Dr Habib on Developments in Palliative Care For Patients With Cancer

M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.

Latest:

Dr Puri on Future Research Directions in SCLC

Sonam Puri, MD, discusses future research directions and ongoing developments in small cell lung cancer.

Sherry Shen, MD

Latest:

Dr Shen on Adjuvant CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Sherry Shen, MD, discusses trials evaluating adjuvant CDK4/6 inhibitors in patients with early-stage, HR-positive, HER2-negative breast cancer.

Robert Alter, MD, John Theurer Cancer Center

Latest:

Incorporating Treatment Advances Into mRCC Management

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

Katelyn M. Atkins, MD, PhD

Latest:

Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric Cancer

Katelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.

Timothy J. Brown, MD

Latest:

Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular Carcinoma

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

Olivia Fankuchen, MD, MS

Olivia Fankuchen, MD, MS, is a clinical fellow in Hematology and Oncology at New York University Langone Health

Latest:

Dr Fankuchen on Practice-Informing Updates to the Thoracic Oncology Treatment Paradigm

Olivia Fankuchen, MD, MS, highlights molecular targets, trial data, and real-world experiences that have immediate implications for the lung cancer field.

Anna Schuh, MD, PhD, MRCP, FRCPath, Oxford University Hospital

Latest:

Key Clinical Data in Relapsed/Refractory CLL

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

Julie K. Heimbach, MD

Latest:

Dr. Heimbach on the Need for Multidisciplinary Care in HCC

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

William M. Sikov, MD

Latest:

Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.

Mustafa Özguröğlu, MD

Latest:

Dr. Ozguroglu on the Individualization of Treatment in NSCLC

Mustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.

Kathryn C. Arbour, MD

Kathryn C. Arbour, MD, is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York.

Latest:

Preliminary Safety and Antitumor Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with KRAS G12D NonSmall Cell Lung Cancer (NSCLC) from a Phase 1 Study in Advanced Solid Tumors

Dr. Kathryn C. Arbour presents preliminary findings from a Phase 1 study showing that zoldonrasib, a selective RAS(ON) G12D inhibitor, demonstrates encouraging antitumor activity and a manageable safety profile in patients with previously treated KRAS G12D–mutant non–small cell lung cancer.

Margaret T. Kasner, MD

Latest:

Practice Pearls for Treatment of Secondary AML in the Community Setting

Panelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.

Makenzi Evangelist, MD

Latest:

Dr. Evangelist on the Goals of the MYLUNG Consortium in Lung Cancer

Makenzi Evangelist, MD, discusses the goals of the MYLUNG Consortium in lung cancer.

Jonathan Webster, MD

Latest:

Role of Age and Ph Status in Blinatumomab Selection in ALL

Jonathan Webster, MD, and Nikesh Shah, MD, discuss who age and Philadelphia chromosome status influence blinatumomab initiation in ALL.

Tracy Ann Politowicz

Latest:

CSF1R Blockade With AMB-05X May Improve Tumor Control in ctDNA+ CRC

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

Latest:

Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.

Chiara Cremolini, MD, PhD, University of Pisa

Latest:

Dr Cremolini on the Utility of xM and xM NeXT Personal Dx MRD Assays

Chiara Cremolini, MD, PhD, discusses the use of the xM and NeXT Personal Dx assays in the detection of minimal residual disease in patients with cancer.

Stefan Maksimovic, MD

Latest:

Dr Maksimovic on a Novel Preclinical Model of Bone Metastasis in ccRCC

Stefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.